International Stem Cell (ISCO) EBITDA (2010 - 2026)
International Stem Cell (ISCO) posted quarterly EBITDA of -$313000.0 for Q4 2025, down 713.73% year-over-year from $51000.0 in Q4 2024, and down 432.98% quarter-over-quarter from $94000.0 in Q3 2025.
International Stem Cell (ISCO) EBITDA (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported EBITDA for 16 consecutive years, with -$313000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA fell 713.73% year-over-year to -$313000.0; the TTM figure through Dec 2025 stood at -$267000.0 (down 292.65% YoY), while the FY2025 annual figure was -$267000.0, down 292.65% from the prior year.
- EBITDA slipped to -$313000.0 in Q4 2025 per ISCO's latest filing, from $94000.0 in the prior quarter.
- Across five years, EBITDA topped out at $167000.0 in Q2 2025 and bottomed at -$623000.0 in Q3 2021.
- Historically, EBITDA has averaged -$155000.0 across 5 years, with a median of -$120500.0 in 2023.
- Annual changes were most pronounced in 2024 — EBITDA slumped 9000.0% — and 2025, when it jumped 204.44%.
- International Stem Cell's EBITDA stood at -$323000.0 in 2021, then jumped by 118.89% to $61000.0 in 2022, then sank by 795.08% to -$424000.0 in 2023, then surged by 112.03% to $51000.0 in 2024, then sank by 713.73% to -$313000.0 in 2025.
- Business Quant data shows ISCO's EBITDA at -$313000.0 in Q4 2025, $94000.0 in Q3 2025, and $167000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | -35,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35,000.00 |
| Dec 31, 2025 | -313,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 167,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Dec 31, 2024 | 51,000.00 |
| Sep 30, 2024 | -90,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Mar 31, 2024 | -178,000.00 |
| Dec 31, 2023 | -424,000.00 |
| Sep 30, 2023 | -97,000.00 |
| Jun 30, 2023 | -144,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Sep 30, 2022 | -300,000.00 |
| Jun 30, 2022 | 31,000.00 |
| Mar 31, 2022 | 25,000.00 |
| Dec 31, 2021 | -323,000.00 |
| Sep 30, 2021 | -623,000.00 |
| Jun 30, 2021 | -406,000.00 |